COVID-19 - APPOINTMENTS AND PROCEDURES
Your health and safety is still our top priority. Appointments are available as video visits, phone calls or in-person visits as needed, with the same safe, world-class care you expect.
Pediatric Open Studies
Registry
COG-APEC14B1
Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study
https://clinicaltrials.gov/ct2/show/NCT02402244
https://clinicaltrials.gov/ct2/show/NCT02402244
CNS
COG-ACNS1422
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
https://clinicaltrials.gov/ct2/show/NCT02724579
https://clinicaltrials.gov/ct2/show/NCT02724579
Oncoceutics-ONC018
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas
https://clinicaltrials.gov/ct2/show/NCT03134131
https://clinicaltrials.gov/ct2/show/NCT03134131
National Children’s Hospital-Head Start IV
Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma And Other Central Nervous System Embryonal Tumors. Clinical And Molecular Risk-Tailored Intensive And Compressed Induction Chemotherapy Followed By Consolidation With Randomization To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
https://clinicaltrials.gov/ct2/show/NCT02875314
https://clinicaltrials.gov/ct2/show/NCT02875314
COG-ACNS1721
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E https://clinicaltrials.gov/ct2/show/NCT03581292
Germ Cell
COG-A031102
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
https://clinicaltrials.gov/ct2/show/NCT02375204
https://clinicaltrials.gov/ct2/show/NCT02375204
COG-AGCT1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
https://clinicaltrials.gov/ct2/show/NCT03067181
https://clinicaltrials.gov/ct2/show/NCT03067181
Hodgkin’s Lymphoma
COG-AHOD1721
Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation
https://clinicaltrials.gov/ct2/show/NCT02927769
https://clinicaltrials.gov/ct2/show/NCT02927769
Leukemia
COG-AALL1521
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02723994
https://clinicaltrials.gov/ct2/show/NCT02723994
COG-AALL1631
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
https://clinicaltrials.gov/ct2/show/NCT03007147
https://clinicaltrials.gov/ct2/show/NCT03007147
COG-ACCL1333
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase
https://clinicaltrials.gov/ct2/show/NCT02369653
https://clinicaltrials.gov/ct2/show/NCT02369653
COG-ADVL1521
A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03190915
https://clinicaltrials.gov/ct2/show/NCT03190915
COG-AALL15P1
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
https://clinicaltrials.gov/ct2/show/NCT02828358
https://clinicaltrials.gov/ct2/show/NCT02828358
COG-AAML1531
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
https://clinicaltrials.gov/ct2/show/NCT02521493
https://clinicaltrials.gov/ct2/show/NCT02521493
COG-AALL1731
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed S tandard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
https://clinicaltrials.gov/ct2/show/NCT03914625
https://clinicaltrials.gov/ct2/show/NCT03914625
COG-AALL1732
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
https://clinicaltrials.gov/ct2/show/NCT03959085
https://clinicaltrials.gov/ct2/show/NCT03959085
COG-ADVL1822
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD Mutations
https://clinicaltrials.gov/ct2/show/NCT03793478
https://clinicaltrials.gov/ct2/show/NCT03793478
Liver
COG-AHEP1531
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
hhttps://clinicaltrials.gov/ct2/show/NCT03533582
hhttps://clinicaltrials.gov/ct2/show/NCT03533582
Multiple
COG-APEC1621
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Document
https://clinicaltrials.gov/ct2/show/NCT03233204
https://clinicaltrials.gov/ct2/show/NCT03233204
COG-AINV18P1
A Phase 1 Study of Palbociclib (IND#141416), a CDK 4/6 Inhibitor, in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
https://clinicaltrials.gov/ct2/show/NCT03792256
https://clinicaltrials.gov/ct2/show/NCT03792256
COG-AGCT1532
A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors
https://clinicaltrials.gov/ct2/show/NCT02582697
https://clinicaltrials.gov/ct2/show/NCT02582697
Neuroblastoma
COG-ANBL00B1
Neuroblastoma Biology Studies
https://clinicaltrials.gov/ct2/show/NCT00904241
https://clinicaltrials.gov/ct2/show/NCT00904241
COG-ANBL1232
Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT02176967
https://clinicaltrials.gov/ct2/show/NCT02176967
COG-ANBL1531
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
https://clinicaltrials.gov/ct2/show/NCT03126916
https://clinicaltrials.gov/ct2/show/NCT03126916
Rhabdomyosarcoma
COG-ARST1431
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
https://clinicaltrials.gov/ct2/show/NCT02567435
https://clinicaltrials.gov/ct2/show/NCT02567435
Solid Tumors
COG-ADVL1622
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02867592
https://clinicaltrials.gov/ct2/show/NCT02867592
COG-ADVL1722
A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
https://clinicaltrials.gov/ct2/show/NCT03441360
https://clinicaltrials.gov/ct2/show/NCT03441360
COG-ADVL1711
A Phase 1/2 Study of Lenvatinib in combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS tumors
https://clinicaltrials.gov/ct2/show/NCT03245151
https://clinicaltrials.gov/ct2/show/NCT03245151
Stem Cell Transplant
NMDP-10-CBA
A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
https://www.clinicaltrials.gov/ct2/show/NCT01351545
https://www.clinicaltrials.gov/ct2/show/NCT01351545
NMDP-RESEARCH DATABASE
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
https://www.clinicaltrials.gov/ct2/show/NCT00495300
https://www.clinicaltrials.gov/ct2/show/NCT00495300
NMDP-SAMPLE REPOSITORY
A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
https://www.clinicaltrials.gov/ct2/show/NCT00495300
https://www.clinicaltrials.gov/ct2/show/NCT00495300
NMDP-17-SIBS
Identifying Predictors of Poor Health-R elated Quality-of-Life among Pediatric Hematopoietic Stem Cell Donor
https://www.clinicaltrials.gov/ct2/show/NCT03718546
https://www.clinicaltrials.gov/ct2/show/NCT03718546
Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050